⌕
Ionis Pharmaceuticals · IONS · Nasdaq
Tenet 27 · Weak
Compare
$28.90−0.54%Market openTenet 27 · Weak
$28.90−0.16 (−0.54%)
Market open · 15-min delayed · as of 1:26 PM ET· Nasdaq · USD

Ionis Pharmaceuticals (IONS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is IONS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● MarketBeatNov 16, 2026 · 12:17 ET
Ionis Pharmaceuticals Sticks to $3 Billion TRYNGOLZA Sales Goal Despite Slow Start

Ionis Pharmaceuticals NASDAQ: IONS remains confident that its triglyceride-lowering drug TRYNGOLZA can generate more than $3 billion in peak annual U.S. sales, even as its launch has started more slowly than expected, CE…

IONS −0.5% todayRead at source ↗
● PRNewsWireNov 16, 2026 · 10:01 ETCOMPANY'S OWN WORDS
Ionis Pharmaceuticals, Inc. (IONS) Securities Investigation Notice - Levi & Korsinsky

TRYNGOLZA sales fell to $9.3 million from $31.8 million a year earlier, and IONS shares dropped on the product-level numbers. Levi & Korsinsky is investigating potential securities law violations on behalf of shareholder…

IONS −0.5% todayRead at source ↗
● Seeking AlphaNov 16, 2026 · 07:52 ET
Ionis Pharmaceuticals, Inc. (IONS) Presents at UBS Global Biopharma Conference 2026 Transcript

Ionis Pharmaceuticals, Inc. ( IONS ) UBS Global Biopharma Conference 2026 November 16, 2026 5:00 AM EST Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Joon Lee - UBS Investment Ba…

IONS −0.5% todayRead at source ↗
● GlobeNewsWireNov 12, 2026 · 16:40 ET
Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS).…

IONS −0.5% todayRead at source ↗
● GlobeNewsWireNov 12, 2026 · 10:12 ETEARNINGS EXPECTED BY FEB 16
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Ionis Pharmaceuticals, Inc. (IONS)

Ionis cut its full-year TRYNGOLZA sales outlook by roughly half as third-quarter sales of the drug only achieved $9.3 million; IONS investors who lost money may have legal rights as an investigation gets underway Ionis c…

IONS −0.5% todayRead at source ↗
● Business WireNov 12, 2026 · 10:00 ETCOMPANY'S OWN WORDS
Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new long-term data for DAWNZERA® (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), to …

IONS −0.5% todayRead at source ↗
● Zacks Investment ResearchNov 11, 2026 · 13:06 ETEARNINGS EXPECTED BY FEB 16
Here's Why Ionis Pharmaceuticals' Stock is Down 28.5% Post Q3 Earnings

IONS plunges as slower Tryngolza sales, reduced guidance and disappointing Wainua royalties rattle investors.…

IONS −0.5% todayRead at source ↗
● Defense WorldNov 11, 2026 · 04:02 ET
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Falls 7.3% Following Analyst Downgrade

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) traded down 7.3% during trading on Tuesday after The Goldman Sachs Group lowered their price target on the stock from $58.00 to $41.00. The Goldman S…

IONS −0.5% todayRead at source ↗
● PRNewsWireNov 10, 2026 · 10:15 ETEARNINGS EXPECTED BY FEB 16
IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals

Ionis topped third-quarter revenue estimates with roughly $243 million in sales, yet IONS shareholders took losses as the same report showed a $110 million net loss and a more than 50% cut to TRYNGOLZA guidance. NEW YORK…

IONS −0.5% todayRead at source ↗
● Business WireNov 10, 2026 · 07:05 ETCOMPANY'S OWN WORDS
Ionis to present at upcoming investor conferences

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: UBS Global Biopharma Conference on M…

IONS −0.5% todayRead at source ↗
● The Motley FoolNov 9, 2026 · 18:53 ETEARNINGS EXPECTED BY FEB 16
Ionis: 3 Key Takeaways for Long-Term Investors

Ionis lowered 2026 TRYNGOLZA revenue guidance to approximately $50 million. DAWNZERA's third-quarter product sales rose 40% to $37 million.…

IONS −0.5% todayRead at source ↗
● Seeking AlphaNov 9, 2026 · 17:35 ETEARNINGS EXPECTED BY FEB 16
Ionis Pharmaceuticals: Q3 Triggers The Latest Selloff On Tryngolza Disappointment

Ionis Pharmaceuticals, Inc. stock plunged over 25% after Q3 earnings, despite beating revenue and EPS expectations and reaffirming 2026 guidance. IONS slashed 2026 Tryngolza sales guidance by more than half due to slower…

IONS −0.5% todayRead at source ↗
● PRNewsWireNov 9, 2026 · 17:35 ETCOMPANY'S OWN WORDS
Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ionis Pharmaceuticals (IONS)

Ionis told investors in July that TRYNGOLZA was "on track" for $100 million to $110 million in 2026 sales. On November 9, it lowered that target to roughly $50 million.…

IONS −0.5% todayRead at source ↗
● Seeking AlphaNov 9, 2026 · 16:40 ETEARNINGS EXPECTED BY FEB 16
Ionis Pharmaceuticals, Inc. (IONS) Q3 2026 Earnings Call Transcript

Ionis Pharmaceuticals, Inc. ( IONS ) Q3 2026 Earnings Call November 9, 2026 9:00 AM EST Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Kyle Jenne - Execu…

IONS −0.5% todayRead at source ↗
● BenzingaNov 9, 2026 · 13:33 ETEARNINGS EXPECTED BY FEB 16
Why Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday?

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) stock is trading at a 52-week low after the company lowered Tryngolza (olezarsen) 2026 product sales guidance.…

IONS −0.5% todayRead at source ↗
● MarketBeatNov 9, 2026 · 12:17 ETEARNINGS EXPECTED BY FEB 16
What Ionis Pharmaceuticals (IONS) Said on Its Q3 Earnings Call

Ionis Pharmaceuticals NASDAQ: IONS lowered its 2026 sales forecast for TRYNGOLZA after a slower-than-expected launch in severe hypertriglyceridemia, while pushing its target for sustained positive cash flow back by a yea…

IONS −0.5% todayRead at source ↗
● Zacks Investment ResearchNov 9, 2026 · 10:31 ETEARNINGS EXPECTED BY FEB 16
Ionis Pharmaceuticals (IONS) Reports Q3 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to …

IONS −0.5% todayRead at source ↗
● Globe News WireNov 9, 2026 · 10:08 ET
Ionis Pharmaceuticals (IONS) Shares Drop Following Sharp Reduction in TRYNGOLZA Sales Forecast – Kehoe Law Firm, P.C. Investigating

PHILADELPHIA, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P. C. is investigating potential securities claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS) following…

IONS −0.5% todayRead at source ↗
● Zacks Investment ResearchNov 9, 2026 · 09:41 ETEARNINGS EXPECTED BY FEB 16
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $0.61 per share a year ago.…

IONS −0.5% todayRead at source ↗
● BarronsNov 9, 2026 · 08:11 ETEARNINGS EXPECTED BY FEB 16
Ionis Slashes Key Drug Revenue Outlook by 50%, Overshadowing Otherwise Solid Earnings

Shares of Ionis Pharmaceuticals sink after it slashes full-year revenue guidance for one of its flagship drugs.…

IONS −0.5% todayRead at source ↗
● Business WireNov 9, 2026 · 07:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Ionis reports third quarter 2026 financial results and highlights progress on key programs

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 2026. “In 2026, we continu…

IONS −0.5% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA15−4.1%
APP3+2.1%
CCB3−1.0%

Article counts from the last market-wide feed page, across every symbol we track and not just IONS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.